New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report
Currado, D.; Margiotta, D.; Conforti, C.; Coppola, R.; Panasiti, V.; Afeltra, A.; Navarini, L.
Scandinavian Journal of Rheumatology 49(1): 75-76
2020
ISSN/ISBN: 0300-9742
PMID: 31262212
DOI: 10.1080/03009742.2019.1594359
Accession: 069111222
PDF emailed within 0-6 h: $19.90
Related References
Apaydin, H.; Dogan, I.; Erten, Şük. 2020: Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series International Journal of Rheumatic Diseases 23(3): 454-456Durmaz, K.; Ataseven, A.; Ozer, I. 2020: Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient Dermatologic Therapy 33(4): E13504
Koller-Smith, L.; Oakley, S. 2022: Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis Rheumatology 61(6): E146-E147
Zheutlin, A.; Schiopu, E. 2018: Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature Case Reports in Rheumatology 2018: 6760806
Famenini, S.; Wu, J.J. 2013: Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases Journal of Drugs in Dermatology: Jdd 12(8): 939-943
Coskun Benlidayi, I.; Kurtaran, B.; Tirasci, E.; Guzel, R. 2020: Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review Rheumatology International 40(10): 1707-1716
Conesa-Nicolás, E.; García-Lagunar, M.ía.H.; Núñez-Bracamonte, S.; García-Simón, M.ía.S.; Mira-Sirvent, M.ía.C. 2020: Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 45(1): 16-21
Delle Sedie, A.; Bazzichi, L.; Bombardieri, S.; Riente, L. 2007: Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab Scandinavian Journal of Rheumatology 36(5): 403-404
Warren, R.B.; Reich, K.; Langley, R.G.; Strober, B.; Gladman, D.; Deodhar, A.; Bachhuber, T.; Bao, W.; Altemeyer, E.; Hussain, S.; Safi, J. 2018: Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database British Journal of Dermatology 179(5): 1205-1207
Alabed, I.B.; Qushmaq, K.A.; Khan, M.A. 2010: Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis Saudi Medical Journal 31(9): 1054-1056
Capkin, E.; Karkucak, M.; Yayli, S.ş; Aydin Çapkin, A.; Tosun, M. 2011: Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis Journal of Clinical Rheumatology: Practical Reports on Rheumatic and Musculoskeletal Diseases 17(5): 293-294
Psarelis, S.; Hajineocli, A.P.D.; Hadjicosta, E.; Elliott, H.St.A.; Johnson, P. 2017: Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review Clinical Rheumatology 36(5): 1197-1199
Watabe, D.; Amano, H. 2021: TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis European Journal of Dermatology: Ejd 31(3): 412-413
Colombo, G.L.; Di Matteo, S.; Martinotti, C.; Jugl, S.M.; Gunda, P.; Naclerio, M.; Bruno, G.M. 2018: Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative Clinicoeconomics and Outcomes Research: Ceor 10: 477-491
Safa, G.; Martin, A.; Darrieux, L. 2011: Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis Journal of Clinical Rheumatology: Practical Reports on Rheumatic and Musculoskeletal Diseases 17(7): 385-386